Covers the decline of cancer death rates, conventional and targeted anticancer drugs, surgical oncology, radiotherapy, chemotherapy, resistance mechanisms, and the history of targeted drugs and EGFR targeting.
Covers sustaining proliferation in cancer cells, growth factors, receptor tyrosine kinases, signal transduction, viral oncogenes, and therapeutic opportunities.
Explores cell adhesion, the ECM, drug delivery, immune engineering, and tissue engineering, emphasizing the dynamic nature of ECM and its crucial role in tissue strength and homeostasis.
